You are here

TGA Internet site archive

The content on this page and other TGA archive pages is provided to assist research and may contain references to activities or policies that have no current application. See the full archive disclaimer.

NDPSC record of reasons, 38th meeting, 17-19 June 2003

National Drugs and Poisons Schedule Committee

17 June 2003

The Record of the Reasons contains the basis of scheduling decisions and other outcomes arising from the meeting. Please note that the Record of the Reasons includes extracts from the NDPSC minutes which have been edited to remove confidential information.

How to access a pdf document

*Large file warning: Attempting to open large pdf files over the Internet within the browser window may cause problems. It is strongly recommended you download this document to your own computer and open from there.

NDPSC Record of reasons, Meeting 38 (pdf,1mb)*

Contents

1.8 NDPSC Working Parties

  • 1.8.1 Trans-Tasman Harmonisation Working Party (Medicines)
    • 1.8.1.1.1 Definition Of Term "Compounded"
    • 1.8.1.1.2 Use Of Term "Cosmetic"/ Hydroquinone
    • 1.8.1.1.3 Aspirin, Paracetamol And Salicylamide - Schedule 4 Entry
    • 1.8.1.1.4 Aspirin - OTC
    • 1.8.1.1.5 Paracetamol
    • 1.8.1.1.6 Pyridoxine, Pyridoxal, Pyridoxamine
    • 1.8.1.1.7 Control Of Injectables
    • 1.8.1.1.8 Antihistamines
    • 1.8.1.1.9 Vitamin A
    • 1.8.1.1.10 Zinc Compounds
    • 1.8.1.1.11 Amphotericin
    • 1.8.1.1.12 NZ Misuse Of Drugs Act And Harmonisation Of Controlled Substances Labelling

2. Proposed Changes/Additions To Parts 1 To 3 And Part 5 Of The Standard For The Uniform Scheduling Of Drugs And Poisons

  • 2.1 Susdp, Part 1
  • 2.2 Susdp, Part 2
    • 2.2.1 Labelling Of Hair Dye Products
  • 2.3 Susdp, Part 3
    • 2.3.1 Packaging Of Schedule 8 Products
  • 2.4 Susdp, Part 5
    • 2.4.1 Eucalyptus And Melaleuca Oil

Top of page

Agricultural/Veterinary, Industrial And Domestic Chemicals

3. Matters Arising From The Minutes Of The Previous Meeting (Consideration Of Post-Meeting Submissions Under 42ZCZ)

  • 3.1 Virginiamycin
  • 3.2 Bacitracin
  • 3.3 Hyaluronic Acid

4. Other Outstanding Matters From Previous Meetings

  • 4.1 Rotenone, Derris And Cubé
  • 4.2 Cubé
  • 4.3 Derris
  • 4.4 Morantel
  • 4.5 Ivermectin
  • 4.6 Chlorinating Compounds

5. Proposed Changes/Additions To The Standard For The Uniform Scheduling Of Drugs And Poisons

  • 5.1 Susdp, Part 4
    • 5.1.1 Creosote
    • 5.1.2 Cassia Oil
  • 5.2 Susdp, Part 5
  • 5.3 Warning Statement And General Safety Directions Established By CPAS For Agricultural And Veterinary Chemicals (Standing Agenda Item)

6. Matters Referred By The Australian Pesticides And Veterinary Medicines Authority

  • 6.1 Azimsulfuron
  • 6.2 Gamma-Cyhalothrin
  • 6.3 1-Methylcyclopropene
  • 6.4 Metarhizium Anisopliae XXXXXXXXX
  • 6.5 Moxidectin
  • 6.6 Bacillus Thuringienses
  • 6.7 Dimethenamid
  • 6.8 Boscalid
  • 6.9 Cinmethylin

Top of page

7. Matters Referred By Office Of Chemical Safety (OCS) Branch

8. Antibiotics For Consideration Following Recommendations Of The Joint Expert Technical Advisory Committee On Antibiotic Resistance (JETACAR)

  • 8.1 Nisin
  • 8.2 Apramycin
  • 8.3 Cefadroxil
  • 8.4 Penethamate Hydriodid
  • 8.5 Thiostrepton
  • 8.6 Phthalylsulfathiazole

9. Other Matters For Consideration

10. Initial Review And/Or Formal Opinions (Ag/Vet, Industrial & Domestic Chemicals)

  • 10.1 Diethylene Glycol Monobutyl Ether

11. Information Items (Ag/Vet, Industrial & Domestic Chemicals)

  • 11.1 Hygromycin

Top of page

Pharmaceuticals

12. Matters Arising From The Minutes Of The Previous Meeting (Consideration Of Post-Meeting Submissions Under 42ZCZ)

  • 12.1 Iron Compounds

13. Other Outstanding Matters From Previous Meetings

  • 13.1 Melia Azedarach
  • 13.2 Mometasone - Paediatric Use
  • 13.3 Azadirachta Indica (Neem)
  • 13.4 Azadirachta Indica (Neem)
  • 13.5 Pseudoephedrine
  • 13.6 Therapeutic Devices
  • 13.7 Dextromethorphan
  • 13.8 Mitragynine
  • 13.9 Nicotine Replacement Therapy
  • 13.10 Budesonide
  • 13.11 Sodium Phosphate
  • 13.12 Lansoprazole

14. Proposed Changes/Additions To The Standard For The Uniform Scheduling Of Drugs And Poisons

  • 14.1 SUSDP, Part 4
    • 14.1.1 Orlistat
    • 14.1.2 Ibuprofen
    • 14.1.3 Nicotine
    • 14.1.4 Levonorgestrel
    • 14.1.5 Mometasone
    • 14.1.6 Codeine/Paracetamol
    • 14.1.7 Budesonide
    • 14.1.8 Budesonide - Paediatric Use
    • 14.1.9 Fluconazole
    • 14.1.10 Trichloroacetic Acid
    • 14.1.11 Paracetamol
    • 14.1.12 Aspirin
    • 14.1.13 Memantine
  • 14.2 Susdp, Part 5
    • 14.2.1 Appendix H

15. Matters Referred By The Australian Drug Evaluation Committee (ADEC)

  • 15.1 New Substances
  • 15.1.1 Deferiprone
  • 15.1.2 Teriparatide
  • 15.1.3 Methyl Aminolevulinate
  • 15.1.4 Vardenafil
  • 15.2 For Information (Substances Already Scheduled)

Top of page

16. Other Matters For Consideration

  • 16.1 1,4-Butanediol, Gamma Aminobutyric Acid, Gamma Butyrolactone, Gamma Hydroxybutyraldehyde And Related Analogues
  • 16.2 Pyridoxine, Pyridoxal, Pyridoxamine

17. Matters Referred By The Medicines Evaluation Committee (MEC)

  • 17.1 Review Of Non-Prescription Analgesics

18. Matters Referred By The Medicines Classification Committee (Mcc) Of New Zealand

  • 18.1 Selenium
  • 18.2 Solanaceous Plants And Alkaloids

22. Amendments To The SUSDP

  • 22.1 Editorial Changes And Errata

24. Attachments

  • Attachment 1 - Ibuprofen Public Submissions - Item 14.1.2
  • Attachment 2 - Levonorgestrel Public Submissions - Item 14.1.4
  • Attachment 3 - Review Of Non-Prescription Analgesics Public Submissions - Item 17.1
    • Paracetamol
    • Nsaids
  • Attachment 4 - Revised Warning Statements - Item 17.1
    • Paracetamol
    • Aspirin
    • Ibuprofen
    • Naproxen
    • Mefenamic Acid

Top of page